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Abstract
Hydroxyurea has proven efficacy in children and adults with sickle cell anemia (SCA), but with considerable inter-individual
variability in the amount of fetal hemoglobin (HbF) produced. Sibling and twin studies indicate that some of that drug
response variation is heritable. To test the hypothesis that genetic modifiers influence pharmacological induction of HbF,
we investigated phenotype-genotype associations using whole exome sequencing of children with SCA treated
prospectively with hydroxyurea to maximum tolerated dose (MTD). We analyzed 171 unrelated patients enrolled in two
prospective clinical trials, all treated with dose escalation to MTD. We examined two MTD drug response phenotypes: HbF
(final %HbF minus baseline %HbF), and final %HbF. Analyzing individual genetic variants, we identified multiple low
frequency and common variants associated with HbF induction by hydroxyurea. A validation cohort of 130 pediatric sickle
cell patients treated to MTD with hydroxyurea was genotyped for 13 non-synonymous variants with the strongest
association with HbF response to hydroxyurea in the discovery cohort. A coding variant in Spalt-like transcription factor, or
SALL2, was associated with higher final HbF in this second independent replication sample and SALL2 represents an
outstanding novel candidate gene for further investigation. These findings may help focus future functional studies and
provide new insights into the pharmacological HbF upregulation by hydroxyurea in patients with SCA.
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Introduction
Sickle cell anemia (SCA) is an inherited blood disorder, affecting
1 in 400 African Americans, causing significant morbidity and
mortality. Although a monogenic disease, individuals with SCA
(usually homozygous HbSS) exhibit wide variability in their
laboratory and clinical phenotypes. One of the most powerful and
reproducible modifiers of disease severity is an individual’s
endogenous level of fetal hemoglobin (HbF) [1]. If produced in
sufficient amounts, HbF is able to prevent the intracellular
polymerization of deoxygenated sickle hemoglobin (HbS), which is
the nidus of the clinical disease process [2,3]. Pharmacologic
induction of HbF is clinically beneficial, and the most widely used
and safest method for increasing HbF levels in patients with SCA
is treatment with hydroxyurea. Currently, it is the only FDA-
approved pharmacologic treatment for induction of HbF in adult
patients with SCA, and is approved by the European Medicines
Agency for both children and adults with SCA. Hydroxyurea
significantly reduces pain and acute chest episodes, the need for
blood transfusions and hospitalizations, and most importantly,
reduces mortality [4–6]. While hydroxyurea has suspected disease
modulating effects outside of HbF induction, the majority of its
benefit is directly related to the amount of HbF produced in
response to the drug [7,8]. There is an inverse relationship
between levels of drug-induced HbF and number of pain episodes,
hospitalizations, and overall mortality [9,10].
Several clinical studies have shown that individual hematolog-
ical responses to hydroxyurea treatment are highly variable, with
induced HbF levels ranging from 10% to greater than 30% HbF
even for compliant patients on similar dosing regimens [11–14].
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Previous efforts to identify predictors associated with final HbF
produced in response to hydroxyurea have identified higher
baseline HbF values, higher white blood cell count (WBC), and
absolute reticulocyte count (ARC) as important factors [13,15,16].
However, none of these parameters can accurately predict the
degree of HbF induction by hydroxyurea in an individual patient.
From analysis of sibling pairs, it is known that the degree of HbF
induction by hydroxyurea has a strong heritable component [17],
indicating that genetic modifiers may have a large effect on drug
response. Identification of specific genetic variants associated with
HbF induction may elucidate reasons for this phenotypic
variability and provide new insights into the drug’s mechanisms
of action related to HbF induction.
The aim of this study was to use a whole exome sequencing
(WES) pharmacogenomics approach to identify genetic predictors
of HbF response to hydroxyurea. Using two prospective pediatric
cohorts with robust HbF phenotype data and standardized dose
escalation regimen to MTD as a discovery cohort, we undertook a
novel unbiased screen to test the entire exome for variants that are
associated with hydroxyurea-induced HbF response levels (as
measured by maximum %HbF at MTD [final HbF] or the change
in %HbF from baseline to final [DHbF]). We focused on genetic
variants with predicted functional effects on protein coding regions
and identified several non-synonymous mutations that may
influence the HbF response to hydroxyurea in children with
SCA. We then validated a coding variant in SALL2 in an
unrelated, ‘‘real-world’’ cohort of children treated with hydroxy-
urea.
Results
Patient characteristics
Overall, both cohorts showed robust response to hydroxyurea
with evidence of substantial individual variability in drug response
(Table 1). All discovery cohort samples were genotyped for
variants in BCL11A (rs1427407, rs4671393, rs11886868,
rs7599488) and HBSIL-MYB (rs9399137, rs9402686); we found
an association with baseline HbF for all BCL11A variants tested
other than rs7599488. There was no significant association
between the BCL11A variants tested and final HbF. No
association with baseline, final or HbF was seen for either
HBSIL-MYB variants tested. Linear association was performed
with BCL11A variants as a covariate, without a significant change
in associations.
At the time of hydroxyurea initiation, the average age of the 171
patients in the discovery cohort was 10.464.5 years of age. The
average age of the 130 patients in the validation cohort was
8.164.0 years. All patients were treated under a similar dose
escalation to MTD regimen according to protocol, or similar
institutional guidelines 18, 19. After a minimum of 6 months on
hydroxyurea therapy, all patients reached a stable MTD (average
25.164.5 mg/kg/day in the discovery cohort, 27.164.3 mg/kg/
day in the validation cohort) with predictable laboratory benefits
(Table 1). The mean increase in HbF was 19.566.6% in the
discovery cohort and 13.967.0% in the validation cohort,
reflecting slight differences between the two groups of patients.
There was evidence of consistent myelosuppression across both
cohorts, however. The baseline HbF, distribution of DHbF at
MTD and final HbF at MTD were all similar to prior reports
(Figure 1, A–C). [15,20].
Whole exome sequencing
All 171 samples in the discovery cohort passed stringent WES
quality control parameters with an average of 92% of the targeted
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exonic regions sequenced at greater than 206 coverage per
individual. We identified a total of 278,639 autosomal variants,
and 127,238 of these variants were non-synonymous or splice site
variants expected to introduce an amino acid change in their
encoded proteins (Table S1). For single variant association testing,
we further filtered the non-synonymous variants (n = 127,238) for
those with a minor allele frequency (MAF) greater than or equal to
2% (n= 38,012). We corrected for any population stratification
using principal component analysis (PCA) performed by the
EIGENSTRAT method.
As our phenotypes of interest are continuous variables, we used
linear regression analysis to test the association of the 38,012
common (MAF$2%) non-synonymous variants using final HbF,
and DHbF as independent, continuous variables. In addition, we
attempted to find rare variants with MAF,2% associated with
drug response by performing burden analysis with SKAT and T2
tests using the DHbF and final HbF phenotypes, but none of the
gene level p-values were significant.
We identified 12 variants associated with DHbF with a p-value
less than 561024 (Table 2). In addition, we identified 13 variants
associated with final HbF, also with a p-value less than 561024
(Table 3). Although none of the p-values achieved genome wide
significance level (p,1.3X1026), these results offered suggestive
signals of potential associations. We used the existing methods of
SIFT and PolyPhen2 [21] for predicting the functional impact of
each non-synonymous variant to estimate which of the 25 variants
had a predicted damaging or benign effect on encoded protein
function (Tables 2 and 3).
From these 25 variants, we identified 13 variants with strongest
association with response to hydroxyurea and predicted to
Figure 1. Comparison of discovery and validation cohorts. A, Baseline, or endogenous HbF for the discovery cohort is shown in binned
histogram, and distribution of baseline HbF in validation cohort by a line plot. B, Delta HbF for the discovery cohort is shown in binned histogram,
and distribution of delta HbF in validation cohort by a line plot. C, Final, or MID HbF for the discovery cohort is shown in binned histogram, and
distribution of final, or MID in validation cohort by a line plot.
doi:10.1371/journal.pone.0110740.g001
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introduce an amino acid change that has a damaging effect on
protein structure or function. We genotyped these 13 variants by
TaqMan PCR in our independent validation cohort of 130
patients with SCA. We found that one of the 13 variants, located
in the SALL2 gene, maintained association with hydroxyurea
response. In the discovery cohort, the P840R variant in the
SALL2 gene (rs61743453) was associated with a higher change in
HbF in response to hydroxyurea (p= 2.3761024, beta value 6.7).
In the validation cohort, this same P840R variant was associated
with a higher final HbF, with a p-value of 0.05, and a beta value of
4.2. Using Fisher’s combined probability test method, a meta
analysis of the association of the SALL2 variant with DHbF in the
discovery and validation sample groups (n = 301) leads to a
combined p-value of 8.3061024. The meta analysis of the
association of SALL2 with final HbF in the discovery and
validation sample groups resulted in a combined p-value of
1.4861024.
Discussion
Many individuals with SCA are prescribed hydroxyurea, and
there is evidence that genetic modifiers affect individual response
[17,22]. In order to identify novel candidate genes and variants
associated with hydroxyurea response, we sequenced the exomes
of 171 individuals enrolled in two prospective clinical trials and
related their sequence variant data to HbF response. This
discovery cohort was obtained from patients treated on protocol,
with the highest level of drug compliance supervision, including
monthly pill counts. Our validation cohort (n = 130) was treated
under guidelines similar to that of the discovery cohort. As
expected, individual MTD was achieved at different hydroxyurea
doses, within a range of 10–35 mg/kg/d, reflecting the typical
range in bioavailability among patients. There was no correlation
between hydroxyurea dose and HbF response (p = 0.56), support-
ing the conclusion that differences in pharmacokinetics and
pharmacodynamics affect HbF levels achieved on hydroxyurea
[22].
Whole exome sequencing permitted analysis of genes beyond a
usual set of a priori biologic candidate genes for this phenotype
and variants across a broad allele frequency spectrum. We
identified multiple non-synonymous variants associated with
DHbF or final HbF (Tables 2 and 3) in the discovery cohort.
We then performed genotyping on a validation cohort for 13
candidate variants with the lowest p-values and were also
predicted to be damaging. Of the 13 variants genotyped, the
variant in SALL2 was associated with a higher HbF in the
discovery cohort, and a higher final HbF at MTD in the discovery
cohort. The validated variant in SALL2 represents a novel variant
not previously implicated in -globin expression or HbF response to
hydroxyurea. Further studies of other sickle cell cohorts treated
with hydroxyurea are needed to confirm this promising associa-
tion.
SALL2 is a multi-zinc finger transcription factor implicated in
hematopoietic cell maturation and cell cycle arrest [23]. It
contains the same conserved 12 amino acid N-terminal motif as
BCL11A [24,25]. This motif has been shown to be essential for
binding of the nucleosome remodeling and deacetylase co-
repressor complex, or NuRD, which includes the histone
deacelylases HDAC1 and HDAC2. Both HDAC1 and HDAC2
have been shown to act as co-repressors of gamma globin [26].
The variant identified here (rs61743453), causes a proline to
arginine change at residue 840 and is predicted to bedamaging to
protein function. This P840R SALL2 variant was associated with a
higher HbF response to hydroxyurea (Figure 2). Further function-
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al studies will help establish the role of SALL2 in HbF induction in
the context of hydroxyurea.
Despite the relatively small sample size, we used the best
genotype-phenotype pairs available from prospectively treated
pediatric patients from two clinical trials for the discovery cohort.
We assembled a validation cohort from patients treated with
hydroxyurea according to standard of care and expert guidelines
in a pediatric hematology center with an established sickle cell
program.
This study may have failed to detect loci with modest effects
because of low statistical power and some associations identified in
the discovery cohort may have failed validation given the small
size of the validation cohort. Accordingly, all of the mutations
identified in the discovery cohort may represent coding variants
worth pursuing in future studies. The data presented here bodes
well for the success of larger collaborative efforts aimed at
identifying genetic modifiers of hydroxyurea response, and serves
as a call for coordinated collaboration among pediatric sickle cell
centers to increase sample size and increase the odds for novel
discovery and translational potential.
Methods
Subjects
The discovery cohort was composed of 171 unrelated children
with SCA; 120 were enrolled in the Hydroxyurea Study of Long-
Term Effects (HUSTLE, NCT00305175); and 51 were enrolled in
the NHLBI-sponsored Stroke with Transfusions Changing to
Hydroxyurea (SWiTCH, NCT00122980). HUSTLE was a single
center trial investigating long term effects of hydroxyurea in SCA,
while SWiTCH was a multi-center trial investigating the use of
hydroxyurea on stroke prevention. HUSTLE and SWiTCH study
patient samples were used with approval from the Baylor College
of Medicine Internal Review Board, protocol H-29047. Patients
and their families in both clinical trials provided written consent
for DNA sample collection, storage and sequencing. Texas
Children’s Hospital Hematology Center patients and their families
provided written consent to whole exome sequencing, posting of
sequences to dbGAP, and data collection under BCM Internal
Review Board protocol H31356. All DNA samples and data in this
study were denominalized for analysis. All 171 individuals had a
known baseline HbF level measured at greater than 3 years of age,
were initially treated with hydroxyurea at 20 mg/kg, and then
dose-escalated to mild myelosuppression using a standardized
regimen [18,19].
The validation cohort contained 130 unrelated children with
SCA followed at the Texas Children’s Hospital Hematology
Center (TCHHC). All patients receiving hydroxyurea at TCHHC
were approached for enrollment in an Internal Review Board-
approved protocol for genetic analysis. They were treated with
hydroxyurea using institutional guidelines rather than a specific
protocol, but all were escalated to MTD following a standardized
regimen as previously described [19]. All patients were treated
with hydroxyurea for at least 6 months prior to the designated
MTD timepoint. Total HbF levels for both discovery and
validation cohorts were measured by HPLC.
Ethics Statement
All patients and their families gave informed consent for
genomic DNA sample collection, storage, and sequencing. The
WES genomic analyses were approved by the Baylor College of
Medicine Institutional Review Board. All DNA samples and data
in this study were denominalized for analysis.
Whole exome sequencing
DNA concentrations were quantified using picogreen fluores-
cent detection method (Quant-iT, Invitrogen). For each DNA
sample, the entire exome was captured using the NimbleGen
VCRome 2.1 capture reagent followed by sequencing on an
Illumina platform using standard chemistries. The sequencing
reads were mapped to Hg19 reference genome using the BWA
[27]. Sample level genome variants were identified and annotated
using the Human Genome Sequencing Center’s integrated
Mercury pipeline which includes quality score recalibration and
insertion/deletion (Indel) realignment, genome variant identifica-
tion by AtlasSNP [28], and annotation using Cassandra software.
A project level variant call format (VCF) was generated for all the
samples, and included variants that were present in at least one
sample. Variants with more than 5% missed genotyping calls were
excluded from analysis. Error threshold for alignment was two
base errors per read with penalties for indels (maximum of 1) are
much more costly than the penalties for SNVs (maximum of 2).
We allowed for read-trimming to 35 bp.
WES genotyping of variants of interest with heterozygosity
scores less than 0.45 were verified by TaqMan genotyping.
TaqMan genotyping assays were performed on an Applied
Biosystem’s StepOne instrument (AB, Foster City, CA). After 40
Figure 2. Effect of SALL2 variant rs61743453 on HbF response to hydroxyurea. A, Effect of rs61743453 on delta HbF in discovery cohort. B,
Effect of rs61743453 on MTD HbF in validation cohort. Variant refers to the Pro840Arg variant; no individuals were homozygous for this change.
doi:10.1371/journal.pone.0110740.g002
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amplification cycles, threshold cycle values were automatically
calculated, and the individual SNP genotypes were called by the
StepOne v2.0 software (AB, Foster City, CA).
Statistical Analysis
Linear regression analysis was used to test the association of the
filtered variants using final HbF and DHbF as independent,
continuous variables. The DHbF and final HbF phenotypes both
had normal distributions, indicating they were suitable for linear
regression analysis (Figure 1); values were adjusted for age and
gender. Principal component analysis (PCA) was performed using
the EIGENSTRAT method, and applied to all models. Quality
control filtering steps, including SNP missingness check, removal
of sex chromosomes, monomorphic site, synonymous and intronic
variant removal, excess heterozygosity filter and minor allele
frequency (MAF) cut-off of 2% and the impact of these filtering
steps on the total number of SNPs, are described in Table S1.
To analyze the effect of rare variants (MAF,2%) on the
phenotypes DHbF and final HbF, we used two gene based tests, a
simple burden test (T2) and SKAT [29,30]. In SKAT and T2
testing, a collection of rare variants within a single gene are tested
for association with the phenotype. The T2 considers those rare
variants with MAF less than 2% and assumes that the effects of all
variants are in the same direction. SKAT is a kernel-based test that
considers rare variants having effects in either direction [29,31].
Both tests considered only non-synonymous variants.
Validation
Genomic DNA from 130 patients from TCHHC collected as a
validation cohort were genotyped by TaqMan or Sanger
sequencing for 13 SNPs with the lowest p-values that were
identified as associated with HbF response to hydroxyurea, non-
synonymous, and damaging. The relationship between genotype
and HbF response to hydroxyurea was analyzed with a one
directional t-test.
Supporting Information
Table S1 Quality control filters used in WES analysis.
Sex chromosomes were removed, as gender did not impact HbF
response to hydroxyurea. Sites with heterzygousto homozygous
ration.0.4 were removed.Variants with MAF,2% were analyzed
by burden testing.
(PDF)
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